Literature DB >> 16012463

Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model.

Kristopher B Deatrick1, Jonathan L Eliason, Erin M Lynch, Andrea J Moore, Nicholas A Dewyer, Manu R Varma, Charles G Pearce, Gilbert R Upchurch, Thomas W Wakefield, Peter K Henke.   

Abstract

HYPOTHESIS: Deep venous thrombosis (DVT) confers vein wall injury associated with fibrosis and extracellular matrix (ECM) turnover, likely mediated by matrix proteases. This study investigated the expression of proteases and collagen involved in early vein wall remodeling.
METHODS: In the mouse, DVT was produced by ligation of the infrarenal inferior vena cava (IVC) or sham operation, and tissue was harvested at 4, 8, and 12 days. The vein wall tissue was processed for real-time reverse transcriptase-polymerase chain reaction (6 to 8 per time point), Western immunoblotting (5 per time point), and gelatin zymography (5 per time point). Analysis of variance was used for multiple comparisons, and a P < .05 was significant.
RESULTS: Thrombus resolution was documented by a 38% decrease in the thrombosed IVC weight from day 4 to day 12 (P = .007). Total vein wall collagen increased over time, with a corresponding increase in procollagen I and III, and expression peaked at 12 days (24-fold and 6.1-fold, respectively, P < .02). Matrix metalloproteinase-2 (MMP-2) gene expression was 23-fold greater at 12 days after thrombus formation compared with sham or 4 days after thrombosis (P < .05). Total MMP-2 activity was also significantly elevated at 12 days compared with sham (P < .05). MMP-9 expression was 19-fold and 27-fold higher at days 4 and 8, respectively, relative to sham (P < .05), with no difference in activity. MMP-14 expression was twofold to 3.6-fold greater at day 12 compared with earlier time points and shams (P < .001), but no differences in protein levels were found. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) protein levels were not significantly different from sham over time; however, the ratio of uPA to PAI-1 was decreased through 8 days.
CONCLUSIONS: Vein wall remodeling after DVT is similar to wound healing and is associated with increased procollagen gene expression and total collagen. It is also associated with increased early MMP-9 expression, followed by MMP-2 expression and activity after DVT resolution. CLINICAL RELEVANCE: Deep vein thrombosis is an often neglected problem that long term is associated with the postphlebitic syndrome of limb swelling, pain, and often ulceration. The basic mechanisms of the vein wall damage that results have not been delineated. The following study describes the vein wall matrix metalloproteinase gene and activity response induced over time in the vein wall after DVT. Additionally, the corresponding collagen upregulation and proximate plasmin system mediators are determined. With this knowledge, potential therapies to reduce vein wall injury directly might be possible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012463     DOI: 10.1016/j.jvs.2005.04.014

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  38 in total

1.  The haploinsufficient Col3a1 mouse as a model for vascular Ehlers-Danlos syndrome.

Authors:  T K Cooper; Q Zhong; M Krawczyk; H-J Tae; G A Müller; R Schubert; L A Myers; H C Dietz; M I Talan; W Briest
Journal:  Vet Pathol       Date:  2010-06-29       Impact factor: 2.221

2.  Divergent effects of Tlr9 deletion in experimental late venous thrombosis resolution and vein wall injury.

Authors:  Nicholas A Dewyer; Osama M El-Sayed; Catherine E Luke; Megan Elfline; Nicolai Kittan; Ron Allen; Adriana Laser; Carson Oostra; Anthony Comerota; Cory Hogaboam; Steven L Kunkel; Peter K Henke
Journal:  Thromb Haemost       Date:  2015-07-16       Impact factor: 5.249

3.  EkoSonic Thrombolysis as a Therapeutic Adjunct in Venous Occlusive Disease.

Authors:  D S Zaghlool; R W Franz; J Jenkins
Journal:  Int J Angiol       Date:  2016-04-03

Review 4.  Venous Thrombosis and Post-Thrombotic Syndrome: From Novel Biomarkers to Biology.

Authors:  Allan K Metz; Jose A Diaz; Andrea T Obi; Thomas W Wakefield; Daniel D Myers; Peter K Henke
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Jul-Sep

5.  Immunohistochemical detection of MMP-2 and MMP-9 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation.

Authors:  Mizuho Nosaka; Yuko Ishida; Akihiko Kimura; Toshikazu Kondo
Journal:  Int J Legal Med       Date:  2010-07-10       Impact factor: 2.686

6.  Intact Toll-like receptor 9 signaling in neutrophils modulates normal thrombogenesis in mice.

Authors:  Osama M El-Sayed; Nicholas A Dewyer; Catherine E Luke; Megan Elfline; Adriana Laser; Cory Hogaboam; Steven L Kunkel; Peter K Henke
Journal:  J Vasc Surg       Date:  2015-10-23       Impact factor: 4.268

Review 7.  Bioengineered in vitro models of thrombosis: methods and techniques.

Authors:  Yu Shrike Zhang; Rahmi Oklu; Hassan Albadawi
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

8.  Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.

Authors:  Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

9.  The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling.

Authors:  Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2013-03-13       Impact factor: 4.268

10.  Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin.

Authors:  Daria K Moaveni; Erin M Lynch; Cathy Luke; Vikram Sood; Gilbert R Upchurch; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2008-03       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.